Adents raises €8.5m from Naxicap et al.

Naxicap will lead the capital increase with a €3.5m contribution, followed by €2m from management, while Omnes and CapHorn will each deploy €1.5m.

Adents intends to use the fresh capital to finance its expansion across the European and the North American market, where subsidiaries Adents Canada and Adents US recently started operating.

A developer of medicine-traceability software used by the pharmaceutical industry, the company foresees expansion opportunities over the next few years. Adents is currently responsible for one billion prescription drug codes, with expectations for growth in a market where identification should be implemented worldwide by the end of 2018, according to the company.

The investment, which increases the total capital received by the business since inception to €15m, is not the first for shareholders Naxicap and Caphorn. According to unquote" data, the former injected €1m into the company via its €8.4m BP Creation fund in February 2011, while the latter invested €2m in May 2013.

Company
Founded in 2007, Adents is a software developer that specialises in product traceability and serialisation. Although the company works with clients from the agri-food, wine, cosmetics and manufacturing sectors, its focus lies with the pharmaceutical industry.

Headquartered in Massy, the business reportedly generated nearly €2m in revenues in 2013.

People
Omnes Capital was represented by managing director Michel de Lempdes and associate Marine Huber. Christophe Devins is CEO and co-founder of Adents.

Advisers
Equity – Reed Smith (Legal).
Company – HBC Avocats (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Expansion
• Technology
• France
• Naxicap
• Omnes Capital